InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Dexter Susan, Chief Technology Officer. Officer active across 1 company, notably Sonnet BioTherapeutics Holdings, Inc.. Cumulatively, 7 reports have been published. Split: 1 buy · 0 sell. Total volume traded: €6k. History available since 25 May 2021. The latest transaction was disclosed on 14 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is openly available.
Declarations7 total
1,452 sharesCommon StockSEC:0001493152-24-048958:0
10,000 shares@ US$0.7020.5% of flowCommon StockSEC:0001493152-23-021430:0
Ideal exit: 10 Mar 2024 (T+270)
14,627 sharesCommon StockSEC:0001493152-23-005468:0
14,627 sharesCommon StockSEC:0001493152-22-036321:0
63,104 sharesCommon StockSEC:0001493152-22-009481:0
10,145 shares@ US$1.5150.0% of flowCommon StockSEC:0001493152-21-013203:0
10,145 shares@ US$1.5150.0% of flowCommon StockSEC:0001493152-21-013203
7 of 7 declarations
About Dexter Susan
Susan Dexter is the Chief Technical Officer at Sonnet BioTherapeutics Holdings, Inc. She is responsible for the company's technological initiatives, ensuring innovation and efficiency in processes. Her expertise in the biopharmaceutical field is crucial for the development of new therapies.
